User profiles for Mark Toshner
 | Mark ToshnerUniversity of Cambridge Verified email at medschl.cam.ac.uk Cited by 36221 |
[HTML][HTML] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South …
…, R Tarrant, EC Thomson, ME Török, M Toshner… - The Lancet, 2021 - thelancet.com
Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …
[HTML][HTML] Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
…, SJ Singh, A Sheikh, D Thomas, M Toshner… - The Lancet …, 2021 - thelancet.com
Background The impact of COVID-19 on physical and mental health and employment after
hospitalisation with acute disease is not well understood. The aim of this study was to …
hospitalisation with acute disease is not well understood. The aim of this study was to …
[HTML][HTML] Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a …
…, RK Sutherland, EC Thomson, ME Török, M Toshner… - The Lancet, 2021 - thelancet.com
Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …
[HTML][HTML] Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised …
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary …
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …
clinical conditions and may be associated with a variety of cardiovascular and respiratory …
[PDF][PDF] Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease
…, EJM Toonen, MP Weekes, B Göttgens, M Toshner… - Immunity, 2021 - cell.com
The kinetics of the immune changes in COVID-19 across severity groups have not been
rigorously assessed. Using immunophenotyping, RNA sequencing, and serum cytokine analysis…
rigorously assessed. Using immunophenotyping, RNA sequencing, and serum cytokine analysis…
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Guidelines summarize and evaluate available evidence, with the aim of assisting health
professionals in proposing the best management strategies for an individual patient with a given …
professionals in proposing the best management strategies for an individual patient with a given …
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy
…, RJ Barst, S Shapiro, H Golpon, M Toshner… - American journal of …, 2010 - atsjournals.org
Rationale: Pulmonary arterial hypertension (PAH) is a progressive condition with a poor
prognosis. Platelet-derived growth factor receptor (PDGFR) signaling plays an important role in …
prognosis. Platelet-derived growth factor receptor (PDGFR) signaling plays an important role in …
[HTML][HTML] Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective …
…, SJ Singh, DC Thomas, M Toshner… - The Lancet …, 2022 - thelancet.com
Background No effective pharmacological or non-pharmacological interventions exist for
patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for …
patients with long COVID. We aimed to describe recovery 1 year after hospital discharge for …
Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the United Kingdom National Cohort
Background— Chronic thromboembolic pulmonary hypertension results from incomplete
resolution of pulmonary emboli. Pulmonary endarterectomy (PEA) is potentially curative, but …
resolution of pulmonary emboli. Pulmonary endarterectomy (PEA) is potentially curative, but …